scispace - formally typeset
C

Cathy Rowe

Researcher at Public Health England

Publications -  18
Citations -  1832

Cathy Rowe is an academic researcher from Public Health England. The author has contributed to research in topics: Medicine & Antibody. The author has an hindex of 6, co-authored 10 publications receiving 666 citations.

Papers
More filters
Journal ArticleDOI

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.

Victoria Hall, +353 more
- 08 May 2021 - 
TL;DR: The SIREN study as discussed by the authors showed that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults in the UK.
Journal ArticleDOI

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN).

V J Hall, +305 more
- 17 Apr 2021 - 
TL;DR: The SARS-CoV-2 Immunity and Reinfection Evaluation study as mentioned in this paper showed that a previous history of SARS infection was associated with an 84% lower risk of infection, with median protective effect observed 7 months following primary infection.
Journal ArticleDOI

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

Mark A. Ainsworth, +130 more
TL;DR: Four commercial, widely available assays and a scalable 384-well ELISA can be used for SARS-CoV-2 serological testing to achieve sensitivity and specificity of at least 98%.
Journal ArticleDOI

Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure

Catherine J. Reynolds, +125 more
- 14 Jun 2022 - 
TL;DR: B and T cell immunity against previous variants of concern was enhanced in triple vaccinated individuals, but magnitude of T and B cell responses against B.1.1 .1.529 spike protein was reduced.
Journal ArticleDOI

COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay: A national systematic evaluation of sensitivity and specificity for mass-testing.

T Peto, +270 more
- 01 Jun 2021 - 
TL;DR: In this article, the authors evaluated the performance of Lateral flow device (LFD) immunoassays for SARS-CoV-2 infection and found that they have promising performance characteristics for mass population testing and can be used to identify infectious positive individuals.